Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
(Other OTC:BIXT),(OTC US:BIXT), – Repurchasing all convertible note overhang, and – Funding pre-clinical and clinical trials – Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and […]